Drug Type Recombinant coagulation factor |
Synonyms Adynovi, Antihemophilic Factor (Recombinant), PEGylated, EHL rFVIII PEG + [15] |
Target |
Mechanism F8 stimulants(Coagulation factor VIII stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (13 Nov 2015), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Rurioctocog alfa pegol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Coagulation Protein Disorders | JP | 05 Dec 2017 | |
Hemophilia A | US | 13 Nov 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 3 | CN | 27 Mar 2023 | |
Advanced Malignant Solid Neoplasm | Phase 3 | CN | 27 Mar 2023 | |
Hemorrhage | Phase 3 | US | 15 Oct 2013 | |
Hemorrhage | Phase 3 | JP | 15 Oct 2013 | |
Hemorrhage | Phase 3 | AU | 15 Oct 2013 | |
Hemorrhage | Phase 3 | AT | 15 Oct 2013 | |
Hemorrhage | Phase 3 | BG | 15 Oct 2013 | |
Hemorrhage | Phase 3 | CZ | 15 Oct 2013 | |
Hemorrhage | Phase 3 | DE | 15 Oct 2013 | |
Hemorrhage | Phase 3 | HK | 15 Oct 2013 |
Phase 1 | Hemophilia A FVIII | - | hovfcynosb(ylgurjuafz) = 3 treatment-emergent adverse events (TEAEs) while receiving efanesoctocog alfa in 1 patient (2 mild and 1 moderate) and none reported for other treatments. No TEAEs were serious, led to treatment discontinuation, or were deemed related to efanesoctocog alfa treatment. blcbzyvqrl (udofoypxok ) | Positive | 14 May 2024 | ||
Phase 3 | 80 | cvshnahkmq(hxdaqqpncn) = Thirteen patients experienced 14 treatment-related adverse events, including 10 cases of FVIII inhibitor development pscdvahewg (guqvrndayf ) | - | 03 Oct 2023 | |||
Not Applicable | 53 | kdhsmwvqoi(gvyqvogvuq) = lxqyxhqsmg plxngxluxn (eqcjiwpryc ) View more | - | 08 Jun 2023 | |||
EHL-FIX factor concentrates | kdhsmwvqoi(gvyqvogvuq) = xfmndeuahl plxngxluxn (eqcjiwpryc ) View more | ||||||
Not Applicable | rurioctocog alfa pegol | - | Adynovi® | ltiqnlmfgq(fmnhaofzwf) = kynqexvhnb eclawqovbo (jgephsgxar ) | - | 12 Jul 2020 | |
ltiqnlmfgq(fmnhaofzwf) = jzovjmewqr eclawqovbo (jgephsgxar ) | |||||||
Phase 2/3 | 10 | jhfyavxmip(dlqorbtrzq) = nfpqeywqjq ltwrvrqwiu (ssuphzznzl ) | Positive | 01 Sep 2019 | |||
Phase 3 | 135 | (BAX 855-Low Level) | ihygvjbqwq(xgfczdggek) = cwgadwosti dyksqxygyn (zumfgwqrkm, apoaupigog - wjflaoetvc) View more | - | 26 Aug 2019 | ||
(BAX 855-High Level) | ihygvjbqwq(xgfczdggek) = mapdmfetpd dyksqxygyn (zumfgwqrkm, dzknjwpkrh - kqeqrveafg) View more | ||||||
Phase 3 | 216 | SHP660 prophylaxis | otwmbnrjey(bwbkymdjjt) = ahqdfznubw acbyszqton (bwwmcurqvc ) View more | - | 10 Jun 2019 | ||
Phase 3 | 216 | xzmgbpawyr(gcdkpjflct) = a non-serious mild AE that resolved ~3-4 weeks after study end cerngnflca (hvqobuwdql ) | - | 10 Jun 2019 | |||
Not Applicable | 12 | jmgjdytmct(aowfkjzehh) = wvkjgncwjc xdqolubaar (jeumiwkskt ) | - | 10 Jun 2019 | |||
Phase 3 | 218 | (BAX 855: Age < 2 Years) | hdypbhgdng(ajlcdbymzg) = cwqufavyvo vypvzxrhwe (ishqftqmgi, xyijobiseg - fpnrqumozp) View more | - | 01 May 2019 | ||
(BAX 855: Age >= 2 to <12 Years) | hdypbhgdng(ajlcdbymzg) = mdurcliuka vypvzxrhwe (ishqftqmgi, bodeurfmcw - eipzigogeo) View more |